This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …

Despite the rapid development of efficient and safe vaccines against COVID-19, the need to
confine the pandemic and treat infected individuals on an outpatient basis has led to the …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

Our study is aimed to access the efficacy and safety outcomes for coronavirus disease 2019
(COVID‐19) patients treated with Paxlovid. According to inclusion and exclusion criteria …

The aim of this study was to investigate the clinical efficacy of a combination of nirmatrelvir
and ritonavir (NMV‐r) for treating COVID‐19 in patients with diabetes mellitus (DM). This …

Objective Autoantibodies and autoimmune diseases after SARS-CoV-2 infection are widely
reported. Given evolving variants, milder infections, and increasing population vaccination …

Although COVID-19 outcomes have improved over the pandemic for patients with RA, some
experience poor acute and postacute outcomes after COVID-19. Clinicians and patients …

Introduction: Vaccination against SARS-CoV-2 and the prevalence of Omicron variants have
reduced the risk of the severe clinical progress of COVID-19. However, the risk of …

Recently, a benefit from administration of a 3‐day course of early remdesivir (ER) in the
outpatients' setting was reported. However, real‐life data on its use is scarce. Therefore, we …